Interleukin-6 receptor blockade for the treatment of NMOSD
Lancet Neurol
.
2020 May;19(5):370-371.
doi: 10.1016/S1474-4422(20)30081-8.
Author
Michael Levy
1
Affiliation
1
Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: mlevy11@mgh.harvard.edu.
PMID:
32333886
DOI:
10.1016/S1474-4422(20)30081-8
No abstract available
Publication types
Comment
MeSH terms
Aquaporin 4
Double-Blind Method
Humans
Immunosuppressive Agents
Neuromyelitis Optica*
Receptors, Interleukin-6
Substances
Aquaporin 4
Immunosuppressive Agents
Receptors, Interleukin-6